The analysis of individuals with severe congenital neutropenia (SCN) may shed light on the delicate balance of factors controlling the differentiation, maintenance and decay of neutrophils. We identify 9 distinct homozygous mutations in the JAGN1 gene encoding Jagunal homolog 1 in 14 individuals with SCN. JAGN1-mutant granulocytes are characterized by ultrastructural defects, a paucity of granules, aberrant N-glycosylation of multiple proteins and increased incidence of apoptosis. JAGN1 participates in the secretory pathway and is required for granulocyte colony-stimulating factor receptor-mediated signaling. JAGN1 emerges as a factor that is necessary in the differentiation and survival of neutrophils. 1 , is characterized by lifethreatening bacterial infections caused by a paucity of mature neutrophils. Studies of individuals with SCN have highlighted principles governing the differentiation, homeostasis and functions of neutrophils 2 , illustrated by roles for ELANE 3, 4 and G6PC3 (ref. 5) in endoplasmic reticulum (ER) stress or HAX1 in mitochondrial function 6 . Genetic defects affecting the endosomal-lysosomal system have been associated with congenital neutropenia (AP3B1 (ref. 7) , LAMTOR2 (ref. 8) , VPS13B 9 and VPS45 (refs. 10,11)); other genes mutated in monogenic SCN include GFI1 (ref. 12 ) and WAS 13 .
SCN, first described by Rolf Kostmann
We herein report that JAGN1 is an ER-resident protein with a function in the early secretory pathway and is critical for the differentiation and maintenance of human neutrophils.
We studied two sibships of Algerian origin (family A; Fig. 1a ) that originated from the same Sephardic community and shared a family name. Consanguinity could not be proven, but several familial links were found. Five children in family A had SCN associated with recurrent, severe bacterial infections ( Table 1) . Histological analysis of bone marrow smears showed maturation arrest at the promyelocyte/ myelocyte stage (Supplementary Fig. 1 ). Sequencing of ELANE, HAX1 and G6PC3 yielded no mutations.
We performed a SNP array-based genetic linkage analysis as described previously 14 , identifying a single perfectly segregating interval between 9.52 Mb and 11.04 Mb on chromosome 3 of Build 36.3 of the NCBI human genome (Fig. 1a) that contained 30 genes (Supplementary Table 1 ). The interval had a multi-marker logarithm of odds (LOD) score of at least 4.5, with a score of at least 6.0 if the sibships were assumed to have a common ancestor (Online Methods).
We performed a literature search to prioritize genes in the linkage interval (Supplementary Table 1 ) for Sanger sequencing. Because aberrant ER function had previously been documented in individuals with mutations in ELANE 3, 4 and G6PC3 (refs. 5,15) , JAGN1-encoding an ER-resident protein originally characterized in Drosophila melanogaster 16 -was an attractive candidate. Sanger sequencing identified one homozygous mutation that segregated perfectly with the disease in both sibships of family A. This mutation, c.3G>A in exon 1 of the JAGN1 gene, leads to disruption of the defined start site of translation (Supplementary Fig. 2 ). For confirmatory evidence, exome sequencing of subject P2 was performed. JAGN1 was the sole 1 0 2 2 VOLUME 46 | NUMBER 9 | SEPTEMBER 2014 Nature GeNetics l e t t e r s gene in Supplementary Table 1 having a variant meeting our filtering  criteria (Online Methods and Supplementary Table 2) .
Thereafter, we assessed a cohort of 74 individuals with SCN for mutations in JAGN1 and identified 9 additional individuals from 8 families bearing homozygous mutations in this gene (Fig. 1b and Table 1 ). The majority of the variants were missense mutations; however, one subject had a nonsense mutation (Fig. 1b, Table 1 , Supplementary  Fig. 3 and Supplementary Table 3) . Immunoblot analysis on subjectderived Epstein-Barr virus (EBV)-immortalized B cell lines using antibodies recognizing the N terminus of JAGN1 showed that different mutations resulted in decreased or non-detectable protein levels in some subjects (P5, P7 and P13) and expression of a mutant and likely non-functional protein in others (P9 and P12) (Fig. 1c) . Immunoblot analysis in subject-derived fibroblast cell lines confirmed the findings for P12 and P13 and showed that the non-frameshift deletion mutation in P14 led to decreased expression of a JAGN1 protein variant of slightly reduced molecular weight ( Supplementary Fig. 4 ).
In the clinical findings (Table 1) , there was not an obvious distinction between individuals with SCN with JAGN1 mutations and those with ELANE mutations 17 or HAX1 mutations 6 of the non-syndromic type, but we occasionally observed abnormalities in bone, pancreas or teeth ( Table 1) . Serial blood counts from several subjects did not show a genotype-phenotype relationship (Supplementary Table 4) . Overall, variability in the level of neutropenia cannot easily be associated with the distinct genotypes. For instance, all affected individuals in family A had the same mutation but exhibited different disease severities. This variability is reminiscent of SCN with ELANE 18 or G6PC3 (refs. 5,19) mutations where no clear association between genotype and phenotype has been observed, suggesting that modifier genes or environmental factors might influence neutrophil counts. Heterozygous JAGN1 mutation carriers were found to have normal differential blood counts (data not shown). Interestingly, the response to recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment was poor in several JAGN1-deficient individuals (Supplementary Table 4) , and, in some individuals, severe bone pain limited the use of rhG-CSF.
JAGN1 orchestrates the concentration of the ER into subcortical clusters during the vitellogenesis stage of Drosophila oogenesis 16 . We performed transmission electron microscopy studies to assess the ultrastructure of the ER and granules in neutrophils. In contrast to the ER in healthy myeloid progenitor cells, the ER in JAGN1-mutant cells appeared enlarged and granules were almost completely absent (Fig. 2a) . Comparison by transmission electron microscopy of peripheral blood neutrophils isolated from a healthy donor before injection with rhG-CSF to those isolated the day after injection did not identify marked differences in the ultrastructure of the cells ( Supplementary  Fig. 5 ), suggesting that G-CSF treatment is not primarily responsible for the altered ultrastructure observed in JAGN1-deficient myeloid cells. Consistent with the observation of increased ER stress, the protein levels of binding immunoglobulin protein (BIP; encoded by the HSPA5 gene) were elevated in JAGN1-mutant granulocytes (Fig. 2b) .
In light of the differences observed in ER structure in JAGN1-mutant granulocytes, we performed comparative global glycomic analyses of peripheral blood neutrophils. The N-glycomes of neutrophils from the clinically healthy mother (Fig. 2c) and father ( Supplementary Fig. 6 ) resembled the N-glycomes of healthy control samples analyzed in earlier studies 20, 21 . We treated an unrelated healthy donor with rhG-CSF 1 d before neutrophil isolation and analyzed the N-glycosylation pattern. No qualitative changes in N-glycan content or in the abundance of multi-fucosylated N-glycan structures were detected (Supplementary Fig. 7 ). In contrast to the healthy donor neutrophils with intact JAGN1, JAGN1-mutant neutrophils from subjects P7 and P8 exhibited anomalous N-glycomic profiles, characterized by a marked reduction in the fucosylation of all multiantennary glycans ( Fig. 2c and Supplementary  Fig. 8 ). Although immature N-glycans were similar in abundance to the ones in healthy control samples (Supplementary Fig. 6 ), their high-mass N-glycomes showed a decrease in the abundance of fucosylated antennae (Fig. 2c) . Studies on unrelated subjects P3 and P12 gave similar findings, with even more pronounced defects (Supplementary Fig. 9 ). In contrast to N-glycan structures, O-glycosylation patterns were similar in cells from affected subjects and controls (Supplementary Fig. 10 ).
Because defective expression of neutrophil elastase (ELANE) has been implicated in the pathomechanism of SCN 22, 23 , we assessed whether JAGN1 had an effect on the expression, glycosylation or localization of ELANE. We analyzed ELANE protein expression by immunoblot and determined its subcellular localization using immunofluorescence in cells in which JAGN1 had been knocked down using small interfering RNAs (siRNAs). No difference in either expression or subcellular localization was seen (Supplementary Fig. 11) . Furthermore, the N-glycosylation profile of ELANE did not depend on JAGN1, as documented by the treatment of cellular extracts with peptide N-glycosylase (PNGase) and endoglycosidase H (EndoH) (Supplementary Fig. 11 ).
We assessed whether JAGN1 deficiency was associated with increased incidence of apoptosis in neutrophils, as seen in individuals with mutations in ELANE 3, 4 npg l e t t e r s Healthy control npg l e t t e r s inhibitor staurosporine, which induces ER stress and can lead to apoptosis. A higher percentage of JAGN1-deficient neutrophils underwent apoptosis in comparison to neutrophils from healthy individuals ( Fig. 2d and Supplementary Fig. 12 ). To assess whether the intrinsic pathway of apoptosis was involved, we treated neutrophils with valinomycin, a potassium-specific transporter that causes dissipation of the mitochondrial membrane potential (∆ψ mt ). JAGN1-deficient neutrophils had a propensity to rapidly depolarize ∆ψ mt ( Fig. 2e and Supplementary Fig. 13 ). Next, we determined the subcellular localization of JAGN1 in mammalian cells. Using a JAGN1-specific polyclonal antibody, we found that JAGN1 was predominantly localized to the ER in HeLa cells (Fig. 3a) . This localization was confirmed in immunofluorescence microscopy studies using constructs encoding GFP-fused JAGN1 in fibroblasts and HeLa cells (Supplementary Fig. 14) .
We sought to determine whether JAGN1 deficiency affected the secretory pathway. We measured the secretion of Gaussia luciferase in HeLa cells in which JAGN1 expression was reduced by RNA-mediated interference. In cells with siRNA-mediated knockdown of JAGN1, the secretion of Gaussia luciferase was significantly reduced (Fig. 3b) . The secretion of proteins, however, was not globally affected; cells with JAGN1 knockdown were not different from controls with respect to the secretion of horseradish peroxidase (HRP; data not shown).
As it was unknown why JAGN1 might be necessary for the secretory pathway, we performed affinity purification followed by mass spectrometry to identify the interaction partners of JAGN1. N-and C-terminal JAGN1 streptavidin-binding peptide-hemaglutinnin (STREP-HA) constructs were generated in HEK293T cells, and tandem affinity purifications were performed as previously described 24 . Three members of the coat protein I (COPI) complex (COPA, COPB2 and COPG2) were identified as interacting with JAGN1 ( Fig. 3c and  Supplementary Data Set 1) . Coimmunoprecipitation experiments confirmed the interactions for both COPA and COPB2 (Fig. 3d) . The COPI complex is known to have a central role in vesicular trafficking from the Golgi complex to the ER 25 .
From clinical trials of rhG-CSF, it is known that 5-10% of both congenital and acquired neutropenia cases respond poorly to rhG-CSF 26 , but no predictive biomarker or molecular mechanism has been found. The majority of individuals deficient for JAGN1 showed no or poor therapeutic response to rhG-CSF. The cognate receptor for G-CSF, G-CSF-R, is heavily glycosylated 27 and is relevant for the development of neutrophils 28 . Global assessment of glycosylation ( Fig. 2c and Supplementary Figs. 6-10 ) implicated a defect in N-glycosylation in neutrophils from affected subjects. We hypothesized that inadequate G-CSF-R-mediated signaling might offer an explanation for the observed defects in neutrophil differentiation. In comparison to neutrophils isolated from healthy individuals, JAGN1-deficient neutrophils derived from affected subjects displayed decreased abundance of G-CSF-R, which was of reduced molecular weight (Fig. 3e) . Upon treatment of proteins with PNGase F, no difference in molecular weight could be demonstrated, suggesting that a defect in N-glycosylation accounts for the aberrant molecular weight of G-CSF-R in affected individuals (Fig. 3e) . It remains difficult to determine the relative contributions of aberrant G-CSF-R signaling and increased apoptosis to neutropenia. We attempted to model JAGN1 deficiency using siRNA-mediated knockdown of JAGN1 in HeLa cells. However, HeLa cells did not recapitulate increased ER stress upon JAGN1 knockdown Fig. 15a ) or easily detectable differences in G-CSF-R N-glycosylation (Supplementary Fig. 15b ), indicating that there might be cell type-specific differences between primary neutrophils and HeLa cells. Knockdown of JAGN1 did not have any influence on the pattern of subcellular GCSF-R distribution (Supplementary Fig. 15c ). Next, we expressed G-CSF-R in HeLa cells and studied STAT3 phosphorylation upon exposure to rhG-CSF in cells transfected with JAGN1-specific siRNA, as suggested by previous research on G-CSF signaling 29 . In contrast to cells transfected with control siRNA, HeLa cells with JAGN1 knockdown had reduced phosphorylation of STAT3 upon exposure to rhG-CSF (Supplementary Fig. 15d) . Collectively, these data suggest decreased G-CSF-R-dependent signaling in the absence of JAGN1. Because of discrepancies between HeLa cells and primary neutrophils, we cannot prove precise molecular mechanisms. Using transmission electron microscopy, biochemical studies and analysis of the N-glycome, we show that JAGN1-deficiency is associated with alterations in the ER and specific granules in human neutrophils. Additionally, JAGN1 deficiency is associated with aberrant neutrophil N-glycosylation. Most striking is a substantial reduction in antennae fucosylation ( Fig. 2c and Supplementary Fig. 8 ).
Other human monogenic diseases have both SCN and aberrant membrane trafficking. Mutations in AP3B1, encoding the β subunit of the adaptor protein 3 (AP3) complex that is involved in protein sorting in the lysosomal compartment and related organelles, are the cause of Hermansky-Pudlak syndrome type II, a syndromic disorder including congenital neutropenia 7, 30 . Reduced expression of the endosomal adaptor protein p14/LAMTOR2 causes a congenital neutropenia syndrome associated with aberrant lysosomal function and defective G-CSF-R signaling 8 . Cohen syndrome is caused by mutations in VPS13B 9 , which encodes a peripheral Golgi membrane protein with a critical function in maintaining the integrity of the Golgi ribbon 31 . The SEC1P/MUNC18-like protein VPS45, cycling on and off membranes during vesicle transport in yeast 32 , is essential for SNARE-mediated membrane trafficking 33 . VPS45 mutations have been identified in individuals with SCN with extramedullary hematopoiesis, suggesting that the encoded protein contributes to the viability and migration of neutrophils 10, 11 . All diseases mentioned in this paragraph are recessive.
Even though JAGN1 is ubiquitously expressed, the only phenotype of JAGN1 deficiency seen in all affected subjects was congenital neutropenia. This cell type specificity could either occur because some other protein carries out the function of JAGN1 in other cell types (as G6PC1 can replace G6PC3, but not in hematopoietic cells 5 ) or because JAGN1 is essential for the secretion and/or membrane localization of proteins necessary for neutrophil function. In line with the latter hypothesis, we could demonstrate aberrant expression of G-CSF-R, a critical cytokine receptor governing the differentiation of neutrophils.
In an accompanying report, Wirnsberger et al. confirm the relevance of Jagn1 for neutrophil granulocytes in a mouse knockout model 34 . Even though, in contrast to humans with JAGN1 mutations, Jagn1-deficient mice do not show neutropenia, they are characterized by increased susceptibility to fungal infections owing to the defective killing capacity of neutrophil granulocytes. Interestingly, granulocyte/macrophage colony-stimulating factor (GM-CSF) but not G-CSF rescues this functional defect in mice 34 , potentially opening a new therapeutic option for individuals with JAGN1-deficient SCN. In summary, by identifying individuals with JAGN1 deficiency, we define a role for JAGN1 in the early secretory pathway that is required for the physiological differentiation and viability of neutrophils.
MeThodS
Methods and any associated references are available in the online version of the paper. 
oNLINe MeThodS
Subjects. All material from affected individuals and healthy donors was obtained with informed assent/consent in accordance with the Declaration of Helsinki. The study was approved by the institutional review boards at Hannover Medical School and the Ludwig Maximilians University Munich.
Genome-wide genetic linkage analysis. For family A, DNA samples from five affected individuals, four parents and one unaffected sibling were genotyped using the Affymetrix 250k StyI SNP mapping array (Gene Expression Omnibus (GEO) platform GPL3718), following the procedures in ref. 35 and those recommended by Affymetrix.
Genotypes were analyzed using the software findhomoz 14 to identify intervals where the affected individuals were homozygous for the same genotypes at consecutive markers and the unaffected individuals had different genotypes for some markers in the interval. The same or a similar homozygosity mapping procedure was used for families B-G to identify an interval on 3p consistent with linkage that included JAGN1. For families E and F, we used another Affymetrix chip (GEO platform GPL6801) for genotyping.
For family A, we computed LOD scores using the software Superlink 36 for some of the 257 SNPs in a 3-Mb region on chromosome 3 that included the minimal linkage region and >500 kb of additional sequence on each side. Twenty of the 257 SNPs had perfect and fully informative segregation.
To model likely consanguinity in pedigrees, we added hypothetical ancestors to the two nuclear family pedigrees. The parents on the left (I-1 and I-2) were assumed to have a pair of great grandparents in common, and the parents on the right (I-3 and I-4) were assumed to have a different pair of great grandparents in common. First, the pedigrees were kept separate and the LOD scores were summed over the two pedigrees. In a model of the unproven shared ancestry of the carrier parents, one great grandparent on the left was assumed to share a pair of great grandparents with a great grandparent on the right, such that the putative founder pair was six generations before the carrier parents. The assumption of common great grandparents to represent likely consanguinity has been used previously 12, 37 .
Disease was modeled as fully penetrant recessive with a disease allele frequency of 0.001. LOD scores depended on the frequency of the diseaseassociated marker alleles. After identifying the 20 SNPs that segregated perfectly, we chose 7 SNPs (Fig. 1a) at which to compute single-marker LOD scores and obtained their affected allele frequencies from HapMap 38 . These seven SNPs were selected as described below such that no two had extreme linkage disequilibrium. The affected allele frequency of each SNP was taken to be the largest (leading to the lowest possible LOD score) frequency among the four populations in HapMap. The multipoint LOD scores reported in the results were computed using the seven selected SNPs.
HapMap Phase 2 had linkage disequilibrium data for four populations (CEU, Utah residents of European ancestry; YRI, Yoruba from Nigeria; JPT, Japanese from Tokyo; CHB, Chinese from Beijing). We considered two SNPs to be in 'extreme linkage disequilibrium' with each other if HapMap explicitly listed an r 2 value of at least 0.8 between the SNPs in any of the four populations or if there was a third SNP with which we considered the first and second SNPs to be in extreme linkage disequilibrium. This means that if there was a chain of SNPs with r 2 values of at least 0.8 connecting the first and second SNP, where each r 2 value is the maximum for the four populations, that the SNPs were considered to be in extreme linkage disequilibrium.
Exome sequencing. Exome sequencing of subject P2 was performed using 50 ng of genomic DNA. DNA was fragmented with simultaneous adaptor ligation (tagmentation) using the Nextera transposome. Subsequently, adaptorligated genomic DNA was enriched for exonic regions during PCR amplification. Clusters were generated using the Illumina cBot Cluster Generation System, following the TruSeq PE Cluster Kit v3 Reagent Preparation Guide. Sequencing was performed in a multiplexed pool of 12 samples distributed on 4 lanes of the flow cell. Reads were demultiplexed and aligned using Burrows-Wheeler Aligner (BWA) software 39 to human reference genome 19. Insertion-deletion realignment was performed as well as recalibration based on Genome Analysis Toolkit (GATK) 40 quality scores. To call singlenucleotide variants (SNVs) and deletions-insertions variants (DIVs), UnifiedGenotyper and GATK Variant quality score recalibration were performed as described previously 41 with minor modifications. Generated lists of SNVs and DIVs were annotated with ANNOVAR 42 using dbSNP Build 137. Variants present in 1000 Genomes Project data (in February 2012) and/or dbSNP Build 137 with minor allele frequency of ≥0.01 were excluded from further analyses; lists were filtered to include only nonsense, missense and splice-site variants present in the shared homozygous region on chromosome 3 at 9.52-11.04 Mb.
Sequence analysis. We used SIFT 43 , PolyPhen-2 (ref. 44) and Consurf 45 to analyze the effects of amino acid substitutions on JAGN1 (Supplementary Table 3 ). We gathered sequences for homologs to JAGN1 (NP_115881.3) by running three rounds of PSI-BLAST 46 with default settings against the NCBI non-redundant database current as of 12 January 2009. We kept only sequences that aligned with an E value of at most 1 × 10 −4 after three rounds of PSI-BLAST. We eliminated sequences that aligned with more than 90% identity with human JAGN1 or with each other, retaining a total of 41 homologs, including human JAGN1. We created a multiple alignment using ClustalW 1.83 (ref. 47 ) with default settings. We ran SIFT 43 , Consurf 45 and PolyPhen-2 (ref. 44 ) on 14 February 2013, using web interfaces. For SIFT and Consurf, we provided the alignment produced by ClustalW.
Immunoblot analyses.
Immunoblotting for the expression levels of BIP and GAPDH was performed as described previously 5 . Total protein was extracted from EBV-immortalized B cell lines and primary fibroblasts from the affected subjects and controls. The primary antibodies used to detect JAGN1 were derived from peptides in the mouse sequence (NP_080641). Polyclonal rabbit antibodies to JAGN1 were raised in a rabbit and were affinity purified against the keyhole limpet hemocyanin (KLH)-coupled peptide ASRAGPRAAGTDGSDFQHR (positions 2-20 of NP_080641) (1:500 dilution). Monoclonal mouse antibody to GAPDH (1:1,000 dilution; Santa Cruz Biotechnology, sc-32233) was used as a loading control.
Electron microscopy. Sample preparation for transmission electron microscopy was performed as described previously 5 . Samples were assessed using a Philips electron microscope 301 (Fei).
Apoptosis assays. Neutrophil granulocytes were isolated from peripheral blood and exposed to staurosporine (2.5 µg/ml; Sigma-Aldrich) to induce apoptosis. Neutrophils were isolated from a healthy donor 1 d after an injection with rhG-CSF. Cells were stained with Annexin V (Life Technologies) and propidium iodide (Sigma-Aldrich) and analyzed by flow cytometry, similarly to previous studies 5 . Flow cytometry data were analyzed using FlowJo version 9.0.1.
Measurement of mitochondrial membrane potential in neutrophil granulocytes. Neutrophil granulocytes were treated with valinomycin (Sigma-Aldrich), a potassium-specific transporter leading to the dissipation of mitochondrial membrane potential (∆ψ mt ). Flow cytometry using the lipophilic cation JC-1 (Life Technologies) was performed as described previously 6 to measure the relative percentage of cells with low ∆ψ mt values.
Cloning of JAGN1. Two fusion constructs were generated: EGFP was cloned upstream (EGFP-JAGN1) or downstream (JAGN1-EGFP) of human JAGN1. The full-length JAGN1 ORF was amplified from cDNA. The PCR primers for EGFP-JAGN1 contained a BglII or SalI restriction site (Supplementary Table 5 ). The PCR primers for JAGN1-EGFP contained an NheI or BamHI restriction site (Supplementary Table 5 ). Both PCR products were subcloned into the pGEM-T Vector System I (Promega). The BglII and SalI digestion sites were used for insertion into pEGFP-C1 plasmid (Clontech Laboratories) to create EGFP-JAGN1. The NheI and BamHI digestion sites and the pEGFP-N1 plasmid (Clontech Laboratories) were used to create JAGN1-EGFP. The Kozak consensus sequence was integrated upstream of the start codon of JAGN1-EGFP. The sequences of the constructs were verified by digestion and sequencing. Vectors from Clontech Laboratories were provided by A. Schambach (Hannover Medical School). 
